GRAY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 Mar 2023 @ 04:00):

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve...

Stats
今日成交量	24 628.00
平均成交量	5 277.00
市值	120.98M
EPS	$0 ( 2024-03-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.267
ATR14	$0.618 (22.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	Wilson Robert N	Buy	506	Common Stock
2023-11-07	Leheny A. Rachel	Buy	2 000	Common Stock
2023-11-06	Roberts Eric W	Buy	2 400	Common Stock
2023-11-03	Roberts Eric W	Buy	11 249	Common Stock
2023-11-03	Roberts Eric W	Buy	3 700	Common Stock

INSIDER POWER
96.28
Last 97 transactions
Buy: 3 103 303 \| Sell: 60 672

音量相关性

長: -0.13 (neutral)

短: 0.37 (neutral)

Signal:(40.58) Neutral

Graybug Vision, Inc. 相关性

10 最正相关
VKTX	0.939
INFI	0.939
POWW	0.935
CTMX	0.932
VSTA	0.931
TTCF	0.926
NOTV	0.925
JWEL	0.924
ACET	0.918
COMT	0.917

10 最负相关
IMMR	-0.919
CCRC	-0.918
IBEX	-0.899
PBFS	-0.89
MGI	-0.883
ISIG	-0.878
ACLX	-0.875
SEDG	-0.873
MSON	-0.866
RMRM	-0.857

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Graybug Vision, Inc. 相关性 - 货币/商品

0.43
( neutral )

0.74
( moderate )

0.22
( neutral )

0.28
( neutral )

-0.01
( neutral )

-0.72
( moderate negative )

Graybug Vision, Inc. 财务报表

Annual	2022
营收:	$2.96M
毛利润:	$2.96M (100.00 %)
EPS:	$-319.50

FY	2022
营收:	$2.96M
毛利润:	$2.96M (100.00 %)
EPS:	$-319.50

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.690

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.25

Financial Reports:

No articles found.

Graybug Vision, Inc.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.